Shares of Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) have been trending higher in the past week with a gain of 15%.
Market Reaction
On Tuesday, SIGY stock ended flat at $0.46 with more than 2K shares, compared to its average volume of 2.2K shares. The stock moved within a range of $0.4600 – 0.4600 after opening trade at $0.46.
- David Humes Appointed as MD to Scientific Advisory Board of Sigyn Therapeutics
Medical technology company, Sigyn Therapeutics, Inc. (OTCMKTS:SIGY), focused on treating pathogen-associated conditions that induce sepsis and life-threatening disorders, has announced the appointment of H. David Humes, MD to its Scientific Advisory Board.
As of now, Dr. Humes is Professor of Internal Medicine at University of Michigan after serving as Chairman of the Department. He is considered a world-renowned scholar in the areas of nephrology, acute renal failure, cell therapy, biomaterials, device formulation, tissue engineering, and extracorporeal therapy. Having founded 4 spinout biomedical companies, he has raised over $100 million of private equity. Apart from that, he is an elected member of the American Society of Clinical Investigation and the American Association of Physicians and a Fellow of American Association for the Advancement of Science and American Institute for Biological and Medical Engineering.
Dr. Humes has years of medical expertise across several industry segments, which makes him an immensely respected thought leader. He has played a crucial role in the oversight of preclinical and animal studies of Sigyn Therapy and is anticipated to be a valuable contributor to the further clinical advancement of Sigyn Therapy.
The Sigyn Therapy is an extracorporeal blood purification technology designed to overcome limitations of previous drugs and devices to treat life-threatening inflammatory disorders. It includes sepsis, which is the leading cause of hospital deaths worldwide.
